NCT06781983 is a Phase 1 clinical trial of IPH4502 in Advanced or Metastatic Solid Tumors, sponsored by Innate Pharma.

Who is sponsoring NCT06781983?

NCT06781983 is sponsored by Innate Pharma.

What drugs are being tested in NCT06781983?

Interventions in NCT06781983: IPH4502.

What condition does NCT06781983 study?

NCT06781983 studies Advanced or Metastatic Solid Tumors.

Is NCT06781983 still recruiting?

NCT06781983 is currently recruiting now. Last updated 5 January 2026.

Last reviewed 2026-01-05 · How we verify

NCT06781983

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of IPH4502 as a Single Agent in Advanced Solid Tumors

Recruiting now Phase 1 Last updated 5 January 2026

What this trial tests

Phase 1 trial testing IPH4502 in Advanced or Metastatic Solid Tumors in 145 participants. Currently enrolling.

Timeline

24 January 2025

Primary endpoint
1 April 2028

1 April 2029

Quick facts

Lead sponsor	Innate Pharma
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	145
Start date	24 January 2025
Primary completion	1 April 2028
Estimated completion	1 April 2029
Sites	7 locations across United States, France

Drugs / interventions tested

IPH4502 — full drug profile →

Conditions studied

Advanced or Metastatic Solid Tumors — all drugs for Advanced or Metastatic Solid Tumors →

Sponsor

Innate Pharma — full company profile →

Who can join

18 and older, any sex, with Advanced or Metastatic Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Safety and Tolerability
Time frame: From time of first dose through treatment period, including the follow-up: up to 24 months
To evaluate the incidence of AEs, SAEs, TEAEs, and DLTs.

Sponsor's own description

This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanced solid tumors that are known to express Nectin-4

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions.
Chen B, Zheng X, Wu J, Chen G, et al · · 2025 · cited 4× · PMID 41184856 · DOI 10.1186/s12943-025-02489-2
Advancements in Targeted Therapies for Colorectal Cancer: Overcoming Challenges and Exploring Future Directions.
Khelwatty SA, Puvanenthiran S, Seddon AM, Bagwan I, et al · · 2025 · cited 1× · PMID 40940907 · DOI 10.3390/cancers17172810
Antibody-drug conjugates targeting the cadherin, claudin and nectin families of adhesion molecules.
Katoh M, Loriot Y, Nakayama I, Hamada A, et al · · 2025 · PMID 41164107 · DOI 10.3389/fmmed.2025.1661016

Verify or expand the search:

Other recruiting trials for Advanced or Metastatic Solid Tumors

Currently open trials in the same condition.

NCT07510828 — PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07205718 — A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07260305 — A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolima · Phase 1 · recruiting
NCT06548217 — A Phase I Study of ONO-4538HSC in Subjects With Advanced or Metastatic Solid Tumors · Phase 1 · active not recruiting
NCT05957081 — Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309 · Phase 1 · recruiting

Other Innate Pharma trials

Trials by the same sponsor.

NCT06088654 — Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma · Phase 1, PHASE2 · terminated
NCT05321147 — Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2 · Phase 1 · completed
NCT03902184 — IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma · Phase 2 · active not recruiting
NCT03665129 — IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors · Phase 1 · terminated
NCT02557516 — Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL · Phase 1, PHASE2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06781983 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Innate Pharma
Last refreshed: 5 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06781983.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing